Publications in 2014 advanced our therapeutic armamentarium for bladder cancer. Molecular characterization might propel us into an era of targeted therapy, and immunotherapeutics might expand our options for patients with metastatic disease. We were also reminded that outcomes are inextricably linked to the quality of the transurethral resections we perform.
- Andrew T. Lenis
- Karim Chamie
